TMPRSS2 inhibitors, Bromhexine, Aprotinin, Camostat and Nafamostat as potential treatments for COVID-19 45SHARES Share via Pinterest Reddit Buffer Xing WhatsApp Flipboard Posted: 4 June 2020 | Arsalan Azimi (Shiraz University of Medical Sciences) | 2 comments Arsalan Azimi explains why inhibiting TMPRSS2 with clinically proven protease blockers could work as a therapeutic strategy against COVID-19. Read the research – click here. With regular news updates and feature articles, our COVID-19 hub has everything you need to keep up to date with R&D during the pandemic. Click below to visit: COVID-19 hub Related topicsDisease research, Drug repurposing, Drug Targets, Research & Development Related conditionsCoronavirus, Covid-19